PubMed Health⌕ Search

Biomedical subjects

D M Bronstein

Publications and source records attributed to D M Bronstein.

At least 19 recordsLinked to original sources
PubMed1995

Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures.

Dopaminergic neurotoxicities of 6-hydroxydopamine (6-OHDA) and the lipopolysaccharide (LPS) were compared in rat mesencephalic cultures plated on poly-L-lysine or on glial monolayers. In the neuron-enriched cultures plated on polylysine, 6-OHDA killed 89% of the tyrosine hydroxylase (TH)-immunopositive neurons, but LPS was not neurotoxic. Conversely, in mixed neuron/glial cultures, 6-OHDA killed only 27% of the TH-immunopositive neurons while LPS killed 70%. The mixed neuronal/glial mesencephalic culture offers a better in vitro model for studying possible mechanisms involved in Parkinson's disease.

Animals↗
PubMed1995

Effects of chronic opiate and opioid antagonist treatment on striatal opioid peptides.

It has long been speculated that feedback inhibition of endogenous opioid neurons may have a role in opiate tolerance and dependence. However, in studies in which opiates or opioid antagonists have been administered to animals, mixed results have been obtained on the ability of these drugs to regulate endogenous opioids. The present studies were undertaken to determine the effects of chronic administration of opiate drugs on opioid peptides. These studies focused on the regulation of prodynorphin (Prodyn) and proenkephalin (Proenk) peptides in striatal tissue. Morphine, whether administered by chronic infusion or repeated injection, was found to increase the concentration of Prodyn peptides in striatum. Increases were statistically significant in the sensorimotor dorsal striatum (caudate-putamen) but not in the limbic-motor ventral striatum (nucleus accumbens-olfactory tubercle). No changes in Prodyn peptides were found following chronic administration of the opioid antagonist naltrexone. No changes in the Proenk peptide MERGL were found following chronic treatment with morphine or naltrexone. These studies are consistent with the suggestion that Prodyn neurons may have a role in the consequences of long-term opiate administration.

Amino Acid Sequence↗
PubMed1995

Effects of sulpiride and SCH 23390 on methamphetamine-induced changes in body temperature and lethality.

Data from human and animal studies suggest that hyperpyrexia contributes to both the neurotoxic and the lethal effects of stimulant drugs such as methamphetamine (METH). Because many of the effects of METH involve the release of dopamine from CNS neurons, we examined the effects of D1 and D2 dopamine receptor antagonists on METH-induced lethality and determined whether these effects correlated with changes in body temperature. In the first set of experiments, we found that the D2 antagonist sulpiride (SUL; 20, 40 or 80 mg/kg) potentiated the lethality caused by a single injection of METH (10 mg/kg). Pretreatment with the D1 antagonist SCH 23390 (SCH; 0.5 mg/kg) reduced the lethality induced by METH alone or by SUL/METH. Other D2 or 5-hydroxytryptamine antagonists prevented, rather than potentiated, METH-induced lethality. In a second set of experiments, rectal temperatures were recorded in METH-injected animals pretreated with SCH or SUL. METH caused a significant increase (i.e., above vehicle-injected levels) in body temperature at 2.5 hr after injection. The effects of SCH or SUL pretreatment on METH-induced changes in body temperature suggest that the lethality-potentiating and -protective effects of SUL and SCH, respectively, were not due to altered thermoregulatory responses. These data support the idea that D1 receptor activation is an important event in the lethality caused by METH and that SUL may potentiate D1 receptor activation by augmenting METH-induced DA release.

Animals↗
PubMed1994

Role of a 35 kDa fos-related antigen (FRA) in the long-term induction of striatal dynorphin expression in the 6-hydroxydopamine lesioned rat.

D1 dopamine (DA) receptor agonists induce the expression of the opioid peptide dynorphin (DYN) in the striatum, an effect accentuated several fold by removing the dopaminergic innervation to the striatum (e.g., by lesioning the DA cell bodies in the substantia nigra [SN]). D1 receptor-mediated effects are thought to involve cAMP and/or phosphoinositides as second messengers. However, it is unclear what third messengers are involved in the regulation of DYN expression. The present experiments evaluated the possible role of two families of immediate-early gene (IEG) proteins, Fos and Jun, in the induction of DYN biosynthesis following repeated treatment with DA agonists. In addition, the role of N-methyl-D-aspartate (NMDA) receptors in modulating DA-induced changes in DYN and IEG protein expression was assessed. Adult male rats received unilateral 6-hydroxydopamine (6-OHDA) or sham lesions of the SN. Following a recovery period, animals were injected twice daily with the DA agonist, apomorphine (APO; 5 mg/kg), for 4 or 7 days. As expected, APO induced DYN biosynthesis, at both the peptide and mRNA level, several fold more in the striatum ipsilateral to the 6-OHDA lesion than in the contralateral control side (or a sham lesioned striatum). These effects appeared to be mediated by D1 receptors since the D1 agonist, SKF 38393 (5 mg/kg), caused the same changes in DYN expression as APO whereas a D2 agonist, quinpirole (1 mg/kg), had no effect. Paralleling the increase in DYN expression, APO also induced the expression of c-Fos and Fos-related antigens (FRA's), in particular a 35 kDa FRA, but had no effect on the expression of various Jun-related IEG proteins (i.e., c-Jun, Jun B, Jun D). Consistent with the notion that Fos and FRA proteins alter transcriptional activity by binding to AP-1 (or AP-1-like) DNA sequences in the promoter regions of target genes, we found that repeated APO treatment caused large increases in AP-1 binding activity in striata ipsilateral to 6-OHDA lesions. These data indicate that repeated activation of D1 receptors increases both the expression of a 35 kDa FRA and AP-1 binding, events which may mediate the large increases in DYN expression in the DA denervated striatum. While co-administration of the NMDA receptor antagonist, MK-801, inhibited APO-induced increases in DYN and Fos/FRA expression in the intact striatum, its only effect in the DA-denervated striatum was a partial (35%) inhibition of the APO-induced increase in DYN-ir concentrations.(ABSTRACT TRUNCATED AT 400 WORDS)

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben↗
PubMed1993

Effects of chronic morphine treatment on beta-endorphin-related peptides in the caudal medulla and spinal cord.

The effects of chronic morphine treatment on beta-endorphin (beta E)-immunoreactive (beta E-ir) peptide levels were determined in the rat caudal medulla and different areas of the spinal cord. Seven days of morphine pelleting had no effect on total beta E-ir peptides in the caudal medulla. In contrast, it significantly increased beta E-ir peptide concentrations in the cervical and thoracic regions of the spinal cord compared with placebo-pelleted controls, whereas in the lumbosacral region this trend did not reach statistical significance. Injections of the opiate receptor antagonist naloxone 1 h before the rats were killed had no effect on the morphine-induced increases in the cord. Chromatographic analyses revealed that enzymatic processing of beta E-related peptides in the spinal cord seemed unaffected by the morphine and/or naloxone treatments. In light of previous data showing that morphine down-regulates beta E biosynthesis in the hypothalamus, the present results suggest that the regulation of beta E-ir peptides in the spinal cord is distinct from that found in other CNS areas. These data provide support for previous results suggesting that beta E-expressing neurons may be intrinsic to the spinal cord.

Animals↗
PubMed1993

Pre- and posttranslational regulation of beta-endorphin biosynthesis in the CNS: effects of chronic naltrexone treatment.

There appear to be two anatomically distinct beta-endorphin (beta E) pathways in the brain, the major one originating in the arcuate nucleus of the hypothalamus and a smaller one in the area of the nucleus tractus solitarius (NTS) of the caudal medulla. Previous studies have shown that these two proopiomelanocortin (POMC) systems may be differentially regulated by chronic morphine treatment, with arcuate cells down-regulated and NTS cells unaffected. In the present experiments, we examined the effects of chronic opiate antagonist treatment on beta E biosynthesis across different CNS regions to assess whether the arcuate POMC system would be regulated in the opposite direction to that seen after opiate agonist treatment and to determine whether different beta E-containing areas might be differentially regulated. Male adult rats were administered naltrexone (NTX) by various routes for 8 days (subcutaneous pellets, osmotic minipumps, or repeated intraperitoneal injections). Brain and spinal cord regions were assayed for total beta E-ir, different molecular weight immunoreactive beta-endorphin (beta E-ir) peptides, and POMC mRNA. Chronic NTX treatment, regardless of the route of administration, reduced total beta E-ir concentrations by 30-40% in diencephalic areas (the arcuate nucleus, the remaining hypothalamus, and the thalamus) and the midbrain, but had no effect on beta E-ir in the NTS or any region of the spinal cord. At the same time, NTX pelleting increased POMC mRNA levels in the arcuate to approximately 140% of control values.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1992

Evidence that beta-endorphin is synthesized in cells in the nucleus tractus solitarius: detection of POMC mRNA.

Evidence from a number of sources indicates that the major site of pro-opiomelanocortin (POMC)-producing cells in the CNS is the arcuate nucleus of the hypothalamus. Using immunocytochemical techniques, a second, smaller group of POMC cells has been detected in the nucleus tractus solitarius (NTS) area of the caudal medulla. However, POMC mRNA has never been reported in the NTS even though it has been found in other extrahypothalamic brain regions. Thus, there is some uncertainty as to whether POMC peptides are actually synthesized de novo in the NTS. In the present study, we used biochemical and anatomical techniques to examine whether POMC mRNA is localized in the NTS. Using in situ hybridization, cells containing POMC mRNA were found in the caudal portion of the NTS. The nucleic acid distribution correlated well with the anatomical distribution of 16k POMC peptide immunoreactivity as determined by immunocytochemistry. Northern analysis revealed that the apparent size of POMC mRNA in the NTS was similar to that found in the arcuate nucleus or the pituitary gland. Results of RNase protection assays using a POMC riboprobe complementary to the 5' end of exon 3 suggested that POMC mRNA in the NTS and arcuate nucleus are identical in this region of the message at least. We also calculated POMC peptide product to mRNA ratios in different tissues and found that NTS cells appear to produce less peptide per mRNA molecule than those in the arcuate nucleus or pituitary gland.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1990

Effects of morphine treatment on pro-opiomelanocortin systems in rat brain.

In previous studies to determine whether chronic opiate administration might negatively feedback upon endogenous opioid systems in the CNS, investigators found no changes in steady-state concentrations of opioid peptides following morphine pelleting. However, since only steady-state levels were measured, it was still not clear whether morphine treatment altered the release and/or biosynthesis of opioid-containing neurons. The goal of the present study was to assess the effects of chronic morphine pelleting on the dynamics of beta-endorphin (beta E) biosynthesis in rats. Hence, at several times during a 7-day morphine treatment, concentrations of total beta E-immunoreactivity (-ir), as well as chromatographically sieved forms of beta E, were determined by RIA, and mRNA levels of pro-opiomelanocortin (POMC) were measured by a solution phase protection assay using a mouse or rat POMC 32P-labelled riboprobe. Concentrations of total beta E-ir or different forms of beta E-ir peptides (i.e. beta-lipotropin, beta E1-31, or beta E1-27/beta E1-26) in the hypothalamus or midbrain following either 1 or 7 days of treatment were similar in morphine- and placebo-pelleted animals. However, a significant increase in total hypothalamic beta E-ir was observed following 3 days of morphine pelleting; chromatographic analyses indicated that this was primarily due to a selective increase in the opiate inactive forms of beta E, i.e. beta E1-27/beta E1-26. After 7 days of pelleting, morphine-treated animals tended to have lower POMC mRNA levels than those of placebo controls (20 to 50% decrease in different studies). The accumulation of hypothalamic beta E-ir at 3 days, and the apparent decline in POMC mRNA levels at 7 days, lend support to the hypothesis that morphine negatively feeds back upon POMC neurons in the brain by inhibiting beta E release and biosynthesis.

Animals↗
PubMed1990

In vitro release of hypothalamic beta-endorphin (beta E) by arginine vasopressin, corticotropin-releasing hormone and 5-hydroxytryptamine: evidence for release of opioid active and inactive beta E forms.

The aims of the present experiments were: 1) to test whether substances which modulate beta-endorphin-immunoreactive (beta E-ir) release from the pituitary gland might act similarly in hypothalamic tissue; and 2) to further characterize the beta E-ir forms which are released from hypothalamus. To address these questions, hypothalamic tissue was incubated in vitro for 10 min periods in either normal media (basal conditions) or in media containing 55 mM KCl or one of several other test substances (stimulation conditions) and release was estimated by measuring the beta E-ir concentrations in the media. Depolarizing concentrations of K+ increased beta E-ir release 2-3 fold over basal levels and this effect appeared to be Ca2(+)-dependent. Dose-dependent increases in beta E-ir release were elicited by nanonolar to micromolar concentrations of either corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), or 5-hydroxytryptamine (5-HT). Conversely, dopamine (1 microM) inhibited both the basal and K(+)-stimulated release of beta E-ir from hypothalamus. Gel filtration chromatography revealed that beta E1-31 and beta E1-27/beta E1-26 were the primary beta E-ir peptides released under either basal or CRH-stimulated conditions; the relative amounts of the beta E-ir peptides found in the media were nearly identical to those found in the hypothalamus itself. This result indicates that the release of different beta E-ir peptides into the media appears to be proportional to the relative amounts stored in tissue.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1990

Light-induced changes in pineal gland N-acetyltransferase activity: developmental aspects.

In adult rats, light acting via a retino-pineal gland neural pathway influences pineal gland biochemistry in two ways: (1) it entrains endogenous circadian rhythms in melatonin biosynthesis to the environmental photoperiod and (2) exposure to even very brief periods of light during the nighttime rapidly suppresses the high levels of nocturnal melatonin production. The present studies were undertaken to determine precisely when photic stimulation first influences the enzymic activity of N-acetyltransferase (NAT), the pineal gland enzyme which rate-limits the overall biosynthesis of the hormone melatonin, and to examine some of the cellular mechanisms which might mediate light-induced effects in neonatal animals. Rats of different ages were either killed during the light phase or were exposed to darkness or light for 1 min during the dark phase of the lighting cycle, returned to their litters in darkness for 30 min and then killed. Pineal gland NAT activity in animals nocturnally exposed to 1 min of light was suppressed in animals 6 days of age or older. Nocturnal light exposure did not suppress enzyme activity in 3- to 5-day-old rats, even though these animals displayed clear light:dark differences in pineal gland NAT activity. Nocturnal light exposure also did not suppress nighttime levels of NAT activity in 7-day-old animals who had been bilaterally enucleated, suggesting that this effect is retinally mediated. Pretreatment of 7-day-old animals with the beta-noradrenoceptor agonist drug, isoproterenol, prevented the nocturnal light-induced suppression of NAT activity.(ABSTRACT TRUNCATED AT 250 WORDS)

Acetyltransferases↗
PubMed1989

Xylamine enhances pineal gland N-acetyltransferase activity in vitro.

1. The action of N-2'-chloroethyl-N-ethyl-2-methyl benzylamine (xylamine) on rat pineal gland sympathetic innervation was examined. 2. This alkylating agent caused a concentration-dependent increase in pineal gland N-acetyltransferase (NAT) activity in neurologically intact pineal glands that was suppressed in glands previously subjected to bilateral superior cervical ganglionectomy. 3. Xylamine-induced elevations in NAT activity were attenuated by beta-noradrenergic antagonist drugs but not by alpha-noradrenergic antagonist drugs. 4. Since pineal gland uptake of radiolabelled norepinephrine (NE) was impaired by xylamine, the drug may increase pineal gland NAT activity by inhibiting NE reuptake into the presynaptic nerve terminal, thereby increasing the amount of the neurotransmitter available to stimulate pinealocyte beta-noradrenoceptors.

Acetyltransferases↗
PubMed1987

Action spectrum of the retinal mechanism mediating nocturnal light-induced suppression of rat pineal gland N-acetyltransferase.

The spectral properties of the retinal mechanism mediating the inhibitory effects of nocturnal light on pineal gland N-acetyltransferase (NAT) activity were determined. Pineal gland NAT activity declined linearly in albino rats exposed to different irradiances of a 460 or 580 nm monochromatic light during the middle of the dark phase of the cycle. The difference in sensitivity to the test lights is that predicted for a photopigment having peak absorbance at 495 nm, suggesting the inhibition of pineal gland N-acetyltransferase activity is mediated by the photopigment found in rat rods.

Acetyltransferases↗
PubMed1986

Visceral nociception in developing rats.

Maturational changes in visceral nociception were measured in developing or adult rats challenged with hypertonic saline or acetylcholine. Chemically induced abdominal constrictions were absent in rats younger than 7 days of age, regardless of the dose of hypertonic saline or acetylcholine used. Age-related increases in the percent of animals responding, the number of abdominal constrictions emitted per responder, and total response duration occurred in animals 10-20 days of age, until adult-like patterns of responding were attained at the time of weaning. Additional changes in the percent animals responding, as well as in the frequency and total duration of abdominal constriction responses, were also seen in postweanling, but not in preweanling, animals. Five-day-old animals did emit audible vocalizations to the intraperitoneal insertion of a hypodermic needle, however, at a time when these animals failed to show observable responses to the noxious visceral stimuli. Hence, mechanisms mediating pain associated with intraperitoneal needle insertion may be functional during the first postnatal week, at a time when mechanisms mediating visceral pain appear to be immature. These differences may be caused by the differential maturation of sensory, neural, or motoric mechanisms important for hypodermic needle insertion versus visceral nociception.

Age Factors↗